Cargando…

Benign descriptors and ADNEX in two‐step strategy to estimate risk of malignancy in ovarian tumors: retrospective validation in IOTA5 multicenter cohort

OBJECTIVE: Previous work has suggested that the ultrasound‐based benign simple descriptors (BDs) can reliably exclude malignancy in a large proportion of women presenting with an adnexal mass. This study aimed to validate a modified version of the BDs and to validate a two‐step strategy to estimate...

Descripción completa

Detalles Bibliográficos
Autores principales: Landolfo, C., Bourne, T., Froyman, W., Van Calster, B., Ceusters, J., Testa, A. C., Wynants, L., Sladkevicius, P., Van Holsbeke, C., Domali, E., Fruscio, R., Epstein, E., Franchi, D., Kudla, M. J., Chiappa, V., Alcazar, J. L., Leone, F. P. G., Buonomo, F., Coccia, M. E., Guerriero, S., Deo, N., Jokubkiene, L., Savelli, L., Fischerova, D., Czekierdowski, A., Kaijser, J., Coosemans, A., Scambia, G., Vergote, I., Timmerman, D., Valentin, L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107772/
https://www.ncbi.nlm.nih.gov/pubmed/36178788
http://dx.doi.org/10.1002/uog.26080
_version_ 1785026679162273792
author Landolfo, C.
Bourne, T.
Froyman, W.
Van Calster, B.
Ceusters, J.
Testa, A. C.
Wynants, L.
Sladkevicius, P.
Van Holsbeke, C.
Domali, E.
Fruscio, R.
Epstein, E.
Franchi, D.
Kudla, M. J.
Chiappa, V.
Alcazar, J. L.
Leone, F. P. G.
Buonomo, F.
Coccia, M. E.
Guerriero, S.
Deo, N.
Jokubkiene, L.
Savelli, L.
Fischerova, D.
Czekierdowski, A.
Kaijser, J.
Coosemans, A.
Scambia, G.
Vergote, I.
Timmerman, D.
Valentin, L.
author_facet Landolfo, C.
Bourne, T.
Froyman, W.
Van Calster, B.
Ceusters, J.
Testa, A. C.
Wynants, L.
Sladkevicius, P.
Van Holsbeke, C.
Domali, E.
Fruscio, R.
Epstein, E.
Franchi, D.
Kudla, M. J.
Chiappa, V.
Alcazar, J. L.
Leone, F. P. G.
Buonomo, F.
Coccia, M. E.
Guerriero, S.
Deo, N.
Jokubkiene, L.
Savelli, L.
Fischerova, D.
Czekierdowski, A.
Kaijser, J.
Coosemans, A.
Scambia, G.
Vergote, I.
Timmerman, D.
Valentin, L.
author_sort Landolfo, C.
collection PubMed
description OBJECTIVE: Previous work has suggested that the ultrasound‐based benign simple descriptors (BDs) can reliably exclude malignancy in a large proportion of women presenting with an adnexal mass. This study aimed to validate a modified version of the BDs and to validate a two‐step strategy to estimate the risk of malignancy, in which the modified BDs are followed by the Assessment of Different NEoplasias in the adneXa (ADNEX) model if modified BDs do not apply. METHODS: This was a retrospective analysis using data from the 2‐year interim analysis of the International Ovarian Tumor Analysis (IOTA) Phase‐5 study, in which consecutive patients with at least one adnexal mass were recruited irrespective of subsequent management (conservative or surgery). The main outcome was classification of tumors as benign or malignant, based on histology or on clinical and ultrasound information during 1 year of follow‐up. Multiple imputation was used when outcome based on follow‐up was uncertain according to predefined criteria. RESULTS: A total of 8519 patients were recruited at 36 centers between 2012 and 2015. We excluded patients who were already in follow‐up at recruitment and all patients from 19 centers that did not fulfil our criteria for good‐quality surgical and follow‐up data, leaving 4905 patients across 17 centers for statistical analysis. Overall, 3441 (70%) tumors were benign, 978 (20%) malignant and 486 (10%) uncertain. The modified BDs were applicable in 1798/4905 (37%) tumors, of which 1786 (99.3%) were benign. The two‐step strategy based on ADNEX without CA125 had an area under the receiver‐operating‐characteristics curve (AUC) of 0.94 (95% CI, 0.92–0.96). The risk of malignancy was slightly underestimated, but calibration varied between centers. A sensitivity analysis in which we expanded the definition of uncertain outcome resulted in 1419 (29%) tumors with uncertain outcome and an AUC of the two‐step strategy without CA125 of 0.93 (95% CI, 0.91–0.95). CONCLUSION: A large proportion of adnexal masses can be classified as benign by the modified BDs. For the remaining masses, the ADNEX model can be used to estimate the risk of malignancy. This two‐step strategy is convenient for clinical use. © 2022 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
format Online
Article
Text
id pubmed-10107772
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley & Sons, Ltd.
record_format MEDLINE/PubMed
spelling pubmed-101077722023-04-18 Benign descriptors and ADNEX in two‐step strategy to estimate risk of malignancy in ovarian tumors: retrospective validation in IOTA5 multicenter cohort Landolfo, C. Bourne, T. Froyman, W. Van Calster, B. Ceusters, J. Testa, A. C. Wynants, L. Sladkevicius, P. Van Holsbeke, C. Domali, E. Fruscio, R. Epstein, E. Franchi, D. Kudla, M. J. Chiappa, V. Alcazar, J. L. Leone, F. P. G. Buonomo, F. Coccia, M. E. Guerriero, S. Deo, N. Jokubkiene, L. Savelli, L. Fischerova, D. Czekierdowski, A. Kaijser, J. Coosemans, A. Scambia, G. Vergote, I. Timmerman, D. Valentin, L. Ultrasound Obstet Gynecol Original Papers OBJECTIVE: Previous work has suggested that the ultrasound‐based benign simple descriptors (BDs) can reliably exclude malignancy in a large proportion of women presenting with an adnexal mass. This study aimed to validate a modified version of the BDs and to validate a two‐step strategy to estimate the risk of malignancy, in which the modified BDs are followed by the Assessment of Different NEoplasias in the adneXa (ADNEX) model if modified BDs do not apply. METHODS: This was a retrospective analysis using data from the 2‐year interim analysis of the International Ovarian Tumor Analysis (IOTA) Phase‐5 study, in which consecutive patients with at least one adnexal mass were recruited irrespective of subsequent management (conservative or surgery). The main outcome was classification of tumors as benign or malignant, based on histology or on clinical and ultrasound information during 1 year of follow‐up. Multiple imputation was used when outcome based on follow‐up was uncertain according to predefined criteria. RESULTS: A total of 8519 patients were recruited at 36 centers between 2012 and 2015. We excluded patients who were already in follow‐up at recruitment and all patients from 19 centers that did not fulfil our criteria for good‐quality surgical and follow‐up data, leaving 4905 patients across 17 centers for statistical analysis. Overall, 3441 (70%) tumors were benign, 978 (20%) malignant and 486 (10%) uncertain. The modified BDs were applicable in 1798/4905 (37%) tumors, of which 1786 (99.3%) were benign. The two‐step strategy based on ADNEX without CA125 had an area under the receiver‐operating‐characteristics curve (AUC) of 0.94 (95% CI, 0.92–0.96). The risk of malignancy was slightly underestimated, but calibration varied between centers. A sensitivity analysis in which we expanded the definition of uncertain outcome resulted in 1419 (29%) tumors with uncertain outcome and an AUC of the two‐step strategy without CA125 of 0.93 (95% CI, 0.91–0.95). CONCLUSION: A large proportion of adnexal masses can be classified as benign by the modified BDs. For the remaining masses, the ADNEX model can be used to estimate the risk of malignancy. This two‐step strategy is convenient for clinical use. © 2022 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology. John Wiley & Sons, Ltd. 2023-01-12 2023-02 /pmc/articles/PMC10107772/ /pubmed/36178788 http://dx.doi.org/10.1002/uog.26080 Text en © 2022 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Papers
Landolfo, C.
Bourne, T.
Froyman, W.
Van Calster, B.
Ceusters, J.
Testa, A. C.
Wynants, L.
Sladkevicius, P.
Van Holsbeke, C.
Domali, E.
Fruscio, R.
Epstein, E.
Franchi, D.
Kudla, M. J.
Chiappa, V.
Alcazar, J. L.
Leone, F. P. G.
Buonomo, F.
Coccia, M. E.
Guerriero, S.
Deo, N.
Jokubkiene, L.
Savelli, L.
Fischerova, D.
Czekierdowski, A.
Kaijser, J.
Coosemans, A.
Scambia, G.
Vergote, I.
Timmerman, D.
Valentin, L.
Benign descriptors and ADNEX in two‐step strategy to estimate risk of malignancy in ovarian tumors: retrospective validation in IOTA5 multicenter cohort
title Benign descriptors and ADNEX in two‐step strategy to estimate risk of malignancy in ovarian tumors: retrospective validation in IOTA5 multicenter cohort
title_full Benign descriptors and ADNEX in two‐step strategy to estimate risk of malignancy in ovarian tumors: retrospective validation in IOTA5 multicenter cohort
title_fullStr Benign descriptors and ADNEX in two‐step strategy to estimate risk of malignancy in ovarian tumors: retrospective validation in IOTA5 multicenter cohort
title_full_unstemmed Benign descriptors and ADNEX in two‐step strategy to estimate risk of malignancy in ovarian tumors: retrospective validation in IOTA5 multicenter cohort
title_short Benign descriptors and ADNEX in two‐step strategy to estimate risk of malignancy in ovarian tumors: retrospective validation in IOTA5 multicenter cohort
title_sort benign descriptors and adnex in two‐step strategy to estimate risk of malignancy in ovarian tumors: retrospective validation in iota5 multicenter cohort
topic Original Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107772/
https://www.ncbi.nlm.nih.gov/pubmed/36178788
http://dx.doi.org/10.1002/uog.26080
work_keys_str_mv AT landolfoc benigndescriptorsandadnexintwostepstrategytoestimateriskofmalignancyinovariantumorsretrospectivevalidationiniota5multicentercohort
AT bournet benigndescriptorsandadnexintwostepstrategytoestimateriskofmalignancyinovariantumorsretrospectivevalidationiniota5multicentercohort
AT froymanw benigndescriptorsandadnexintwostepstrategytoestimateriskofmalignancyinovariantumorsretrospectivevalidationiniota5multicentercohort
AT vancalsterb benigndescriptorsandadnexintwostepstrategytoestimateriskofmalignancyinovariantumorsretrospectivevalidationiniota5multicentercohort
AT ceustersj benigndescriptorsandadnexintwostepstrategytoestimateriskofmalignancyinovariantumorsretrospectivevalidationiniota5multicentercohort
AT testaac benigndescriptorsandadnexintwostepstrategytoestimateriskofmalignancyinovariantumorsretrospectivevalidationiniota5multicentercohort
AT wynantsl benigndescriptorsandadnexintwostepstrategytoestimateriskofmalignancyinovariantumorsretrospectivevalidationiniota5multicentercohort
AT sladkeviciusp benigndescriptorsandadnexintwostepstrategytoestimateriskofmalignancyinovariantumorsretrospectivevalidationiniota5multicentercohort
AT vanholsbekec benigndescriptorsandadnexintwostepstrategytoestimateriskofmalignancyinovariantumorsretrospectivevalidationiniota5multicentercohort
AT domalie benigndescriptorsandadnexintwostepstrategytoestimateriskofmalignancyinovariantumorsretrospectivevalidationiniota5multicentercohort
AT fruscior benigndescriptorsandadnexintwostepstrategytoestimateriskofmalignancyinovariantumorsretrospectivevalidationiniota5multicentercohort
AT epsteine benigndescriptorsandadnexintwostepstrategytoestimateriskofmalignancyinovariantumorsretrospectivevalidationiniota5multicentercohort
AT franchid benigndescriptorsandadnexintwostepstrategytoestimateriskofmalignancyinovariantumorsretrospectivevalidationiniota5multicentercohort
AT kudlamj benigndescriptorsandadnexintwostepstrategytoestimateriskofmalignancyinovariantumorsretrospectivevalidationiniota5multicentercohort
AT chiappav benigndescriptorsandadnexintwostepstrategytoestimateriskofmalignancyinovariantumorsretrospectivevalidationiniota5multicentercohort
AT alcazarjl benigndescriptorsandadnexintwostepstrategytoestimateriskofmalignancyinovariantumorsretrospectivevalidationiniota5multicentercohort
AT leonefpg benigndescriptorsandadnexintwostepstrategytoestimateriskofmalignancyinovariantumorsretrospectivevalidationiniota5multicentercohort
AT buonomof benigndescriptorsandadnexintwostepstrategytoestimateriskofmalignancyinovariantumorsretrospectivevalidationiniota5multicentercohort
AT cocciame benigndescriptorsandadnexintwostepstrategytoestimateriskofmalignancyinovariantumorsretrospectivevalidationiniota5multicentercohort
AT guerrieros benigndescriptorsandadnexintwostepstrategytoestimateriskofmalignancyinovariantumorsretrospectivevalidationiniota5multicentercohort
AT deon benigndescriptorsandadnexintwostepstrategytoestimateriskofmalignancyinovariantumorsretrospectivevalidationiniota5multicentercohort
AT jokubkienel benigndescriptorsandadnexintwostepstrategytoestimateriskofmalignancyinovariantumorsretrospectivevalidationiniota5multicentercohort
AT savellil benigndescriptorsandadnexintwostepstrategytoestimateriskofmalignancyinovariantumorsretrospectivevalidationiniota5multicentercohort
AT fischerovad benigndescriptorsandadnexintwostepstrategytoestimateriskofmalignancyinovariantumorsretrospectivevalidationiniota5multicentercohort
AT czekierdowskia benigndescriptorsandadnexintwostepstrategytoestimateriskofmalignancyinovariantumorsretrospectivevalidationiniota5multicentercohort
AT kaijserj benigndescriptorsandadnexintwostepstrategytoestimateriskofmalignancyinovariantumorsretrospectivevalidationiniota5multicentercohort
AT coosemansa benigndescriptorsandadnexintwostepstrategytoestimateriskofmalignancyinovariantumorsretrospectivevalidationiniota5multicentercohort
AT scambiag benigndescriptorsandadnexintwostepstrategytoestimateriskofmalignancyinovariantumorsretrospectivevalidationiniota5multicentercohort
AT vergotei benigndescriptorsandadnexintwostepstrategytoestimateriskofmalignancyinovariantumorsretrospectivevalidationiniota5multicentercohort
AT timmermand benigndescriptorsandadnexintwostepstrategytoestimateriskofmalignancyinovariantumorsretrospectivevalidationiniota5multicentercohort
AT valentinl benigndescriptorsandadnexintwostepstrategytoestimateriskofmalignancyinovariantumorsretrospectivevalidationiniota5multicentercohort